Active Studies

The objective of this study is to assess dual-task costs in older adults with and without Type2 Diabetes, and to determine how dual-task cost is influenced by cognitive workload and sleep quality.

What would be required from participants?

• To attend on a single visit at our laboratory at KUMC (approximately 1.5 hour)

• To be screened for diabetes peripheral neuropathy

• To perform a sleep quality questionnaire

• To perform a series of thinking/memory questions and manual tasks involving lifting light objects

The goal of this clinical research study is to learn if Niraparib can help to control metastatic pancreatic cancer. The safety of this drug will also be studied. Niraparib is FDA approved and commercially available for the treatment of ovarian cancer. Its use in this study is investigational.

Our study is interested in understanding how individuals with Autism Spectrum Disorder (ASD) and healthy individuals perform on tests of thinking and motor skills and how their brains may act differently during these kinds of tests.

 

 If you're interested in participating, please click this link to fill out our online screener: https://redcap.kumc.edu/surveys/?s=JATAPCALRN

The objective of this study is to compare the efficacy of Cognitive Behavioral Training for Insomnia (CBT-I) on improving cognitive function in older adults with symptoms of insomnia, determine the association between change in sleep measures and change in cognitive function, and to examine the efficacy of CBT-I on reducing the rate of Aβ deposition. Participants, ages 60-85, will be randomly assigned to a six-week CBT-I training or to an active control group. A sub-group of fifty CBT-I participants will undergo Florbetapir-Positron-emission tomography (PET) imaging during the one-year reassessment to examine the efficacy of CBT-I on reducing the rate of Aβ accumulation from baseline to one year post CBT-I.

The purpose of this study is to obtain information pertaining to the occurrence of antibodies
to investigational SPK-3006 and GAA, GAA activity and GAA antigen levels in the usual care
setting of Late-Onset Pompe Disease (LOPD) participants on an enzyme replacement regimen.
Additionally, a careful evaluation of laboratory and functional testing in patients with LOPD
may provide information to better understand the disease features and better drive the design
of a future interventional investigational gene therapy trial. An understanding of the
underlying status of liver and muscle health in individuals with LOPD may also inform best
surveillance during the conduct of gene therapy trials.

Pages